Researchers have identified the SHP protein as a key regulator that suppresses cartilage-degrading enzymes and slows osteoarthritis progression.

Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who ...

A major report highlighting how engineering biology can drive economic growth, improved health outcomes and environmental ...

This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and ...

The CHOP's research team findings support the hypothesis that rare AAV integration can contribute to human oncogenesis, which ...

RB042 Phase 1 trial advances into multiple ascending dose study cohorts, demonstrating safety and tolerability to date. Dr.

Phase 3 AD trial: 85% of patients enrolled; full enrollment on track in summer 2026PD open-label extension (OLE) study: 40% of patients enrolled; full enrollment on track in fourth quarter 2026New Dru ...

Neurizon receives Bellberry HREC approval for phase 1 NUZ-001 oral liquid formulation study: Melbourne, Australia Friday, May 15, 2026, 16:00 Hrs [IST] Neurizon Therapeutics Limit ...

Regenxbio announces positive results from pivotal phase III AFFINITY DUCHENNE study of RGX-202 to treat Duchenne muscular dystrophy: Rockville, Maryland Friday, May 15, 2026, 14:0 ...

SN BioScience Inc., a clinical-stage biotechnology company based in South Korea, announced today that it has initiated the ...

First Tracks launched April 20th with a two-year cash-runway to advance ANB033 through celiac disease and eosinophilic ...

The court also ordered its senior registrar to keep the paper-book and the loose documents provided by the petitioner in a ...